Novavax, Inc. (Nasdaq: NVAX) is a company focused on creating differentiated, value-added pharmaceutical and vaccine products and technologies: which include the virus-like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells, as well as novel vaccine adjuvants based on Novasomes®, non-phospholipidvesicles and dendrimer technologies.
Such technologies the company is using in developing a pandemic flu vaccine against H5N1, H9N2 and other avian influenza viruses and a seasonal flu vaccine against human influenza. A goal that now will push through smoothly after the successful completion of the renovation and validation for current "Good Manufacturing Practices" (cGMP) compliance of its industrial facility located at One Taft Court,
For more information on the FDA's Draft "Guidance to the Industry: Clinical Data to Support the Licensure of Pandemic Influenza Vaccines" issued March 2006 for comment can be obtained at the FDA Web site.
Source: Novavax Press Release
.jpg)
Comment Preview